0JXZ Stock Chart & Stats
€24.70
€0.10(0.38%)
At close: 4:00 PM EST
€24.70
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€22.62 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.77B
Enterprise Value€1.52B
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.6
Beta0.62
Next Earnings
Aug 10, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.75Price Target Upside-7.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.8
Revenue Forecast (FY)€23.87M
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance Sheet / Low LeverageExceptionally low leverage and a large equity base provide durable financial flexibility: it supports continued R&D and clinical investment without urgent refinancing, lowers bankruptcy risk, and gives management optionality for strategic deals or capital raises over the next 2–6 months.
High And Improving Profitability MarginsSustained very high gross margins and recent positive net and EBIT margins indicate strong pricing power and operating leverage. This structural margin profile can fund operating priorities and improve resilience, making earnings more durable if revenue trends stabilise.
Strong Historical Revenue ExpansionA large reported revenue growth rate reflects meaningful recent commercial progress or one-off revenue expansion, demonstrating the company's ability to scale sales and capture market share. This track record supports medium-term revenue potential if growth drivers persist.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent cash burn means the business is not self-financing its operations or investments. Over 2–6 months this forces reliance on balance sheet liquidity or external financing, which constrains strategic flexibility and raises dilution or refinancing risk if cash flows don’t improve.
Uneven Revenue Momentum; Recent TTM DeclineTop-line volatility and a recent TTM decline complicate forecasting and capital allocation. In a 2–6 month horizon, inconsistent revenue undermines confidence in sustaining margins and may impede scaling efforts or delay payback on current investments.
Historical Earnings Volatility Despite Strong SolvencyPast earnings swings imply execution and demand risks; even with a strong balance sheet, recurring volatility can erode long-term return expectations. Over months, this raises the chance that improved margins will revert absent sustained revenue and cash-generation improvements.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €22.62 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.77B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Aug 10, 2026 which is in 35 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on May 06, 2026. The company reported €0.21 earnings per share for the quarter, beating the consensus estimate of -€0.815 by €1.025.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.7.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €0.21 in its last earnings report, beating expectations of -€0.815. Following the earnings report the stock price went down -4.189%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€22.75
▼(-7.89% Downside)
Technical Analysis
Options Prices
Currently, No data available
---